Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy

Overview
This review sorts 117 publications, 73 of them with full expansion protocols, by the equipment used. G-Rex® processes come out above 2000-fold for TIL, T cells and NK cells in 2-3 weeks; hollow-fiber systems at 100-200-fold in 1-2 weeks; and Prodigy cultures generally below 50-fold after 10-13 days.
What this paper found
This review compares bioreactor technologies used to expand lymphocytes for adoptive cell therapy and concludes that tailored solutions and knowledge-based process control are needed. Drawing on 117 publications meeting eligibility criteria, of which 73 had detailed expansion protocols and results, it groups them into rocking motion reactors, hollow fiber systems, alternative perfusion systems, stirred reactors, G-Rex®-based processes and Prodigy-based processes. It reports that G-Rex® processes reach expansion above 2000 fold for TIL, T cells and NK cells within 2–3 weeks, hollow fiber cultures typically give 100 to 200 fold in 1 to 2 weeks, and Prodigy cultures generally stay below 50 fold after 10–13 days. Stirred reactors have been applied to T and NK cells, but cell-to-cell contact-intensive cultures have not yet been executed successfully.
Note: This is a literature review; results from different studies are not easily comparable because stimulation, supplementation and starting material differ between protocols.
Lymphocytes are still frequently expanded totally or partly in conventional, static culture flasks or similar vessels. — Oscar Fabian Garcia-Aponte, Christoph Herwig, Bence Kozma, Journal of Biological Engineering
Study details
- Authors
- Oscar Fabian Garcia-Aponte, Christoph Herwig, Bence Kozma
- Institution
- Research Area Biochemical Engineering, Institute of Chemical, Environmental and Bioscience Engineering, TU Wien, Vienna, Austria
- Journal
- Journal of Biological Engineering
- Year
- 2021
- Cell type(s)
- NK Cells, T-Cells, TIL Cells
Explore related
Full citation
Garcia-Aponte OF, Herwig C, Kozma B. Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy. J Biol Eng. 2021;15(1):13.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.